跳转至内容
Merck
CN

P2371

帕米膦酸钠 二钠盐 水合物

≥95% (NMR), Bone resorption inhibitor, solid

别名:

3-氨基-1-羟基-1-膦酰基丙烷膦酸 二钠盐 水合物

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式(希尔记法):
C3H9NO7P2Na2 · xH2O
化学文摘社编号:
分子量:
279.03 (anhydrous basis)
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
EC Number:
260-647-1
MDL number:
Assay:
≥95% (NMR)
Form:
solid
Quality level:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

帕米膦酸钠 二钠盐 水合物, ≥95% (NMR), solid

Quality Level

assay

≥95% (NMR)

form

solid

color

white

mp

300 °C

solubility

H2O: 28 mg/mL

originator

Novartis

storage temp.

2-8°C

SMILES string

O.[Na+].[Na+].NCCC(O)(P(O)([O-])=O)P(O)([O-])=O

InChI

1S/C3H11NO7P2.2Na.H2O/c4-2-1-3(5,12(6,7)8)13(9,10)11;;;/h5H,1-2,4H2,(H2,6,7,8)(H2,9,10,11);;;1H2/q;2*+1;/p-2

InChI key

TVQNUQCYOOJTMK-UHFFFAOYSA-L

Biochem/physiol Actions

帕米膦酸二钠具有阻断Wnt和β-catenin信号转导的能力,其可调节骨髓间充质干细胞(BMMSC)的成骨分化。它还可以减少胆红素受损的细胞凋亡,并帮助了来自人乳牙的干细胞发育成牙本质功能障碍。
骨吸收抑制剂;法呢基二磷酸合酶的抑制剂(IC50= 200 nM)。

Features and Benefits

该化合物由 Novartis 开发。想要浏览其他由制药公司开发的化合物以及已批准药物/候选药物清单,请单击此处
这种化合物是环核苷酸研究的特色产品。点击此处发现更多特色环核苷酸产品。在sigma.com/discover-bsm可了解更多关于生物活性小分子的其他研究领域。

pictograms

Exclamation mark

signalword

Warning

hcodes

Hazard Classifications

Acute Tox. 4 Oral

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Gloves


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Evangelos Terpos et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(18), 2347-2357 (2013-05-22)
The aim of the International Myeloma Working Group was to develop practice recommendations for the management of multiple myeloma (MM) -related bone disease. An interdisciplinary panel of clinical experts on MM and myeloma bone disease developed recommendations based on published
George Bullock et al.
Materials (Basel, Switzerland), 13(9) (2020-05-07)
Medication-related osteonecrosis of the jaw (MRONJ) is a side effect of bisphosphonate therapy, characterised by exposed necrotic bone. The soft tissues of the oral mucosa no longer provide a protective barrier and MRONJ patients experience pain, infections and difficulties eating.
Yan Wang et al.
PloS one, 7(9), e44868-e44868 (2012-10-03)
It is unclear whether the new anti-catabolic agent denosumab represents a viable alternative to the widely used anti-catabolic agent pamidronate in the treatment of Multiple Myeloma (MM)-induced bone disease. This lack of clarity primarily stems from the lack of sufficient
Ratna Chatterjee et al.
British journal of haematology, 159(4), 462-471 (2012-09-13)
This study aimed to evaluate bone remodelling disorders in thalassaemia by using pamidronate (PD) infusion with or without hormone replacement therapy (HRT) as a diagnostic-therapeutic tool. In this prospective study, 24 adult thalassaemia major (TM) and 10 thalassaemia intermedia (TI)
Marcin Kos et al.
Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 71(6), 1010-1016 (2013-03-16)
Bacterial colonization of the denuded bone in bisphosphonate-related osteonecrosis of the jaw suggests that bisphosphonates increase bacterial adhesion and biofilm formation. This study evaluated the adhesion of gram-positive and gram-negative bacteria on hydroxyapatite coated with pamidronate, one of the most

商品

Cyclic nucleotides like cAMP modulate cell function via PKA activation and ion channels.

全球贸易项目编号

货号GTIN
P2371-10MG04061834362951
P2371-100MG04061832981918

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持